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Detection and characterization of clonal immunoglobulin (IG)/T-cell receptor (TR) 
rearrangements and translocations in lymphoproliferative neoplasms provides critical 
information in the diagnostic pathway and is a valuable tool to address research questions 
involving B and T cell lymphoproliferative disorders (LPD).1,2 This includes ascertaining the 
clonal nature of lymphoid proliferations3,4, characterization of translocations in lymphomas 
and leukemias4, characterization of CDR3 regions for MRD target identification5 and 
stereotyping analysis6, amongst others. Until recently, collecting this information required a 
combination of different methodologies, such as Gene-scanning/heteroduplex analysis, FISH 
and Sanger sequencing. The incorporation of next generation sequencing (NGS) in clinical 
laboratories opens up new possibilities where an integrated NGS approach can provide data 
on sequence and structural variation in a single assay, including translocations and IG/TR 
rearrangements, and has been shown to be successful for the characterisation of IG 
translocations in myeloma and lymphomas.7,8   
 
Within the EuroClonality-NGS consortium, we have designed a capture-based protocol 
covering the coding V, D and J genes of the IG/TR loci, as well as switch regions in the IGH 
locus. This design allows the identification of D-J and V-(D)-J rearrangements as well as 
chromosomal translocations involving IG/TR genes by sequencing through the breakpoint 
regions in genomic DNA. We piloted this approach using a sample cohort (n=24) consisting 
of 3 B-cell precursor acute lymphoblastic leukemias (BCP-ALL), 4 Burkitt lymphomas, 8 
chronic lymphocytic leukemias (CLL), 2 splenic marginal zone lymphomas (SMZL), 2 
diffuse large B cell lymphomas (DLBCL), 2 follicular lymphomas (FL), 2 T-cell acute 
lymphoblastic leukemias (T-ALL) and 1 T-cell non-Hodgkin lymphoma (T-NHL). Twenty-
one cases were known to carry a translocation arising within the IG/TR loci with the 
remaining three cases being included for their well characterised D-J or V-(D)-J gene 
rearrangements. Libraries were constructed from 1 µg of genomic DNA which was 
fragmented to an average of 200 bp using an E220 Focussed-ultrasonicator (Covaris, 
Woburn, MA, USA). Fragmented DNA was processed using the TruSeq DNA LT sample 
preparation kit (Illumina, Cambridge, UK). Libraries were hybridized to a custom-designed 
EZ SeqCap gene panel (Roche-Nimblegen, Madison, MI, USA) which encompassed 180 kb 
containing the V, D, J and constant regions of the IG and TR loci as well as the switch 
regions of the IGH locus. Enriched samples were sequenced on a MiSeq (Illumina) using 
75bp or120bp paired-end reads. Reads were aligned to the reference genome (hg19) with 
translocations and variants called using a previously described bioinformatics pipeline9. The 
average depth of sequencing in the 21 samples with successful NGS results was 322x. IG/TR 
gene rearrangements were also determined by PCR and Sanger sequencing using the 
BIOMED-2 protocol in 14 cases1. For the detailed characterization of D-J/V(D)J gene 
rearrangements the IMGT V-Quest software was used5. IG/TR translocations had been 
previously determined by routine FISH, karyotyping and/or Sanger sequencing in the 
referring laboratories. 
 
In 18 out of 21 samples with a known translocation, identified by either FISH or karyotyping, 
the breakpoints were identified by the NGS capture panel (Table 1). Out of the 3 samples that 
failed to produce results, 2 concerned fresh frozen samples from lymphomas with degraded 
and low-quantity DNA (<500ng total DNA and < 1kb median fragment size by TapeStation 
analysis) and 1 was due to a technical error due to evaporation during the hybridisation step 
in a BCP-ALL case.  
 
Out of the 18 samples, 15 (83%) were from patients with B-cell LPD (BCLPD), of which 11 
had well-known translocations partners: CRLF2 (2 BCP-ALL), MYC (4 Burkitt), BCL11A (1 
CLL), BCL2 (2 CLL and 1 DLBCL) and CCND3 (1 SMZL). In these samples, the exact 
location of different breakpoints could be delineated from the sequencing reads. In addition, 
analysis of the reads mapping to the IGH locus showed that in 7 cases (47%) the break 
involved an IGHJ and/or IGHD gene whereas in 8 cases (53%) the break lay within the 
switch regions. The NGS capture approach thus provided additional information about the 
timing and aberrant cellular processes giving rise to the translocation, either occurring at the 
time of the D-J or V-DJ recombination or during class-switch recombination7. Identification 
of the specific breakpoint was possible in the majority of cases, although due to the high 
homology between the different switch regions it was not always possible to specifically map 
reads unequivocally.  
 
In 3 of the 15 BCLPD samples (20%) only karyotyping results were available and the 
location of the breakpoint on the partner chromosome as defined by NGS was mapped to 
chromosomes 5q14.2 (SMZL), 1q32.1 (CLL) or 16q22.1 (CLL). However, no known 
lymphoma-associated genes lay in proximity to these breakpoints highlighting the potential 
of this approach to identify novel translocation partners and/or mechanisms of disease. 
Alternatively, these chromosomal alterations may represent “passenger” recombination 
events, where genomic rearrangements are present in the IGH loci due to a by-product of the 
processing of double-stranded DNA breaks by the enzymatic machinery, not resulting in an 
oncogenic translocation. 
 
In the remaining BCLPD sample -a case with DLBCL- NGS analysis was able to detect a 
translocation between IGH and chromosomal location 6p25. The break occurred downstream 
of EXOC2 and thus in the vicinity of IRF4, a constellation similar to the activating IRF4 
translocations described in germinal-centre derived LPD10. FISH analysis of the material 
using an IGH break-apart probe (Abbott Molecular, Maidenhead, UK) showed the presence 
of a translocation with no evidence of a MYC, BCL2 or BCL6 rearrangement, supporting the 
NGS findings and highlighting the strength of NGS capture approaches to identify novel or 
uncommon translocation partners and breakpoints in one single analysis.  
 
The three T-cell LPD (TCLPD) included in the cohort consisted of two T-ALL and one T-
NHL case. The translocations in each of the cases arose from either the TRD, TRG or the 
TRB locus emphasising the benefit of the NGS capture panel to be able to interrogate all 
IG/TR loci in samples from different diseases at the same time. In all three samples the NGS 
approach identified the same rearrangement as demonstrated previously by karyotyping: 
t(7;10)(q34;q24) involving TRBJ2-5 and TLX1, inv(14)(q11;q32) involving TRDD3 and 
BCL11B11 and inversion on chromosome 7 involving TRGV8 (7p14.2) and TRBJ2-7 
(7q34)12. 
 
In all 14 samples with well-characterized V-(D)-J and/or D-J IG gene rearrangements by 
PCR and Sanger sequencing, NGS was able to detect the same IGH and IGK/IGL gene 
rearrangements (Table 2), including 4 CLL cases with hypermutated VDJ rearrangements 
(90% to 96% homology). All cases included in the study were diagnostic material with 
tumour infiltration >60% and in the remaining six samples clonal V-(D)-J rearrangement(s) 
were also identified by NGS, consistent with the clonal nature of the disorder; however, PCR 
and Sanger sequencing data were not available for these six cases for comparison due to 
insufficient DNA. This version of the EuroClonality-NGS panel did not include probes for 
the intron RSS or KDE sequence, explaining why the intronRSS-KDE rearrangement found 
by Sanger sequencing in a Burkitt lymphoma case was not detected by the NGS approach. In 
two CLL cases, a total of three IGK locus gene rearrangements were detected by NGS in 
each case, raising the possibility of more than one clonal population being present, as 
previously described in chronic BCLPD13. Additionally, aberrant clonal rearrangements were 
seen that were not detected with conventional PCR based approaches (e.g. IGKV to IGK 
intron), which warrant further analysis. In the three TCLPD cases, Sanger sequencing 
identified TRDV1-TRDJ1 (T-ALL with inv(14)), a TRBV5-TRBJ1-6 (T-ALL with t(7;10)) 
and a TRBV5-1-TRBJ2-5 (T-NHL) rearrangements, all of which were also identified in the 
NGS analysis. In addition, NGS reads demonstrated functional rearrangements in TRG in 
both T-ALL cases (TRGV11-TRGJ1 and TRGV2-TRGJ1/J2), and a non-functional TRDV1-
TRDJ1 rearrangement in one of the T-ALL. No confirmatory Sanger sequencing analysis 
was feasible for these latter rearrangements due to insufficient DNA.  
 
In summary, this pilot study demonstrates the ability of the EuroClonality-NGS capture 
approach to simultaneously detect IG/TR translocations and V-(D)-J rearrangements in 
diagnostic clinical specimens from a range of malignant LPD, including cases with 
hypermutated VDJ rearrangements. By using capture probes against the V, D and J gene 
regions of the TR and IG loci (with additional switch regions for IGH), clonal 
rearrangements and chromosomal translocations arising from these loci can be detected and 
at the same time the genomic breakpoint sequence involved in the rearrangements and 
translocations can be identified without the need for additional tests. Other technologies such 
as target locus amplification (TLA) have also recently demostrated the ability to detect 
structural variants and translocations in cancer14. An important advantage of these approaches 
lies in the fact that no prior knowledge of the translocation partner is needed and therefore, 
novel or rare chromosomal rearrangements can also be identified by this method, improving 
the diagnostic value. Sequencing of the V-(D)-J gene rearrangements in any of the IG/TR 
loci can be used not only to assess clonality and enable a more in-depth analysis of clonal 
relationships and clonal evolution, but also to identify targets for minimal residual disease 
(MRD) monitoring and analyse the IG/TR repertoire of diverse lymphoid populations. 
Additional information, for example the somatic hypermutation status of the IGHV-IGHD-
IGHJ gene rearrangements, relevant for prognosis in CLL6 can also be obtained. A new 
version of this EuroClonality-NGS panel is being designed to include common non-IG/TR 
translocations as well as genes relevant for diagnosis and prognosis in LPDs and a clinical 
multi-centre validation study is now underway within the EuroClonality-NGS consortium.  
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Table 1: Translocations detected by Karyotyping or FISH and the EuroClonality NGS panel. 
      NGS Capture results 
  
    der(IG/TR) der(partner chromosome) 
Sample Diagnosis Karyotyping or 
FISH results 
Break 1 Location Break 2 Location  Break 1 Location Break 2 Location  
EC20 BCP-ALL t(X;14)(p22;q32) IGHJ6 chr14:106329465 CRLF2 chr.X/Y:1358468 IGHD3-9 chr14:106370544 CRLF2 chrX/Y:1358472 
EC19 BCP-ALL t(Y;14) IGHJ5 chr14:106330070 CRLF2 chr.X/Y:1333757 IGHD6-19 chr14:106357574 CRLF2 chrX/Y:1333695 
EC21 Burkitt 
lymphoma 
t(8;14) ND ND ND ND IGHA1 chr14:106177928 MYC chr8:128749373 
EC23 Burkitt 
lymphoma 
t(8;14) IGHG1 and 
IGHD2-2 
chr14: complex MYC chr8:128746892 IGHG2/3* chr14 MYC chr8:128746903 
EC18 Burkitt 
lymphoma 
t(8;14) IGHJ4 chr14:106330462 MYC chr8:128746504 ND ND ND ND 
EC17 Burkitt 
lymphoma 
t(8;14) IGHA1  chr14:106177015 MYC chr8:128749477 IGHA1 chr14:106177496 MYC chr8:128749448 
EC30 CLL t(2;14)(p13;32) IGHM  chr14:106327487 BCL11A chr2:60781261 IGHM chr14:106327500 BCL11A chr2:60781273 
EC31 CLL t(14;18)(q32;q21) IGHJ6 chr14:106329459 BCL2 chr18:60793474 ND ND ND ND 
EC29 CLL t(14;18)(q32;q21) IGHJ5 chr14:106330071 BCL2 chr18:60769465 IGHD2-15 chr14: 106363819 BCL2 chr18:60769465 
EC5 DLBCL t(14;18) IGHJ5 chr14:106330072 BCL2 chr18:60793494 IGHV3-21 chr14:106691673 BCL2 chr18:60793498 
EC34 SMZL t(6;14)(p21;q32) IGHA2* chr14 CCND3 chr6:41942244 ND ND ND ND 
EC3 DLBCL IGH break‡ IGHM chr14:106326706 IRF4 chr6:472682 IGHG4* chr14 EXOC2 chr6 
EC25 CLL t(14;16)(q32;q22) ND ND ND ND IGHD2-2 chr14: 106382689 unknown† chr16:69479932 
EC24 CLL t(1;14)(q32;q32) IGHM or 
IGHA1* 
chr14 unknown† chr1:206286226 IGHM or 
IGHA1* 
chr14 unknown† chr1:206286210 
EC33 SMZL t(5;14)(q13;q32) IGHM chr14:106326138 unknown† chr5:88608990 IGHM chr14:106326162 unknown† molecular1 
EC11 T-ALL inv14/t(14;14) TRDD3 chr14:22918106 BCL11B chr14:99689173 ND ND ND ND 
EC12 T-ALL t(7;10) TRBJb2.5 chr7:142494805 TLX1 chr10:102902431 ND na ND ND ND 
EC14 T-NHL inv7 TRGV8 ND TRBJb2.7 ND ND ND ND ND 
* Alignment equivocal due to sequence homology. † No known lymphoma/leukaemia-associated gene in proximity. ‡ demonstrated by FISH IGH break-apart 
probe. ND: exact breakpoint could not be determined due to insufficient or lack of aligned reads.  
Table 2: IGH and IGK rearrangements detected by Sanger sequencing and the EuroClonality NGS panel. 
 
   
IGH IGK 
   
Allele 1 Allele 2 Allele 1 Allele 2 
Sample  Diagnosis Results IGHV IGHD IGHJ IGHV IGHD IGHJ IGKV IGKJ IGKV IGKJ 
EC21 Burkitt Lymphoma 
Sanger Seq. 3-15 3-22 4 - 3-16 4     
NGS 3-15 3-22 4 - 3-16 4 1-9 2 D1-13 2 
EC23 Burkitt Lymphoma 
Sanger Seq. 3-23 - 4 - - - 4-1 3 - - 
NGS 3-23 4-23 4 - - - 4-1 3 - - 
EC18 Burkitt Lymphoma 
Sanger Seq. 3-22 6-13 4 - - - 4-1 2 intronRSS-KDE* 
NGS 3-22 6-13 4 - - - 4-1 2 intronRSS/VK1-8 
EC30 CLL 
Sanger Seq. 4-39 6-25 4 - - -     
NGS 4-39 6-25 4 - - - 4-1 1 - - 
EC31  CLL 
Sanger Seq. 3-30 2-2 4 - - -     
NGS 3-30 na 4 - - - 4-1 3 KDE-VK1-8 
EC29 CLL 
Sanger Seq. 5-51 4-17 4 - - -     
NGS 5-51 4-17 4 - - - 1-16 4 - - 
EC25  CLL 
Sanger Seq. 4-34 5-18 6 - - -     
NGS 4-34 5-18 6 - 2-8 4 4-1 2 - - 
EC24 CLL 
Sanger Seq. 4-61 6-19 5 5-51 5-12 4     
NGS 4-61 6-19 5 5-51 5-12 4 2-30 2 4-1 3 
EC33 SMZL 
Sanger Seq. 3-23 3-22 3 - - -     
NGS 3-23 3-22 3 - - - 1-5 1 - - 
EC32  SMZL 
Sanger Seq. 2-5 6-19 2 - - -     
NGS 2-5 6-19 2 - - - 2-28 2 - - 
EC34 SMZL 
Sanger Seq. 5-51 4-4 6 - - -     
NGS 5-51 4-4 6 - - - - - - - 
EC27 CLL 
Sanger Seq. 4-39 6-13 5 - - -     
NGS 4-39 6-13 5 - 5-18 6 1-39 4-1† 
1 
2 1-17 1 
EC26 CLL Sanger Seq. 4-39 6-13 5 - - -     
NGS 4-39 6-13 5 - 2-2 5 1-39 5-2† 
1 
1 1D-8 2 
EC28 CLL 
Sanger Seq. 4-39 6-13 5 - - -     
NGS 4-39 6-13 5 - 3-16 4 1-39 4 1-17 1 
EC20 BCP-ALL 
Sanger Seq.           
NGS 3-30 2-2 5 - - - KDE-VK2-30 and IGKV7-3-IGKV2-28 
EC22 BCP-ALL 
Sanger Seq.           
NGS FAIL FAIL FAIL FAIL FAIL FAIL FAIL FAIL FAIL FAIL 
EC19 BCP-ALL 
Sanger Seq.           
NGS 3-30 3-9 5 - - - 3-20 1 KDE-IGKJ2 and  KDE-IGKV3-20 
EC17 Burkitt Lymphoma 
Sanger Seq.           
NGS 3-72 6-13 4 - 3-22 4 1-5 4 KDE-VK3-11 
EC3 DLBCL 
Sanger Seq.           
NGS 1-46 6-6 4 - - - 3-7 4 - - 
EC5 DLBCL 
Sanger Seq.           
NGS 3-48 - 4 - - - 1-6 3 - - 
 
Blank cells: No Sanger sequencing data available. *intronRSS-Kde not detectable by NGS as no probes against this region were included in the original panel 
design. † More than 2 rearrangements detected. 
  
